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1. Introduction 
Ulcerative colitis (UC) is a chronic, immunologically-mediated disorder which affects the 
gastrointestinal tract. This disease is characterized by inflammation of the colonic or rectal 
mucosa, leading to rectal bleeding, diarrhea, and abdominal pain. UC, along with Crohn’s 
disease, is referred to as inflammatory bowel disease. The specific cause of this disease is 
unknown, but research has suggested that it is most likely initiated by a combination of host 
susceptibility and environmental triggers. These factors lead to an overly-aggressive T-cell 
response to bacteria in the gastrointestinal tract. An abnormal ratio between beneficial and 
detrimental microbes in the gut may also contribute to the development of this disease, as 
well as defects in the function of the intestinal mucosal barrier. No medical cure has been 
developed for UC; treatment focuses on inducing and maintaining remission (Sartor, 2006).  
Anti-inflammatory drugs, particularly those that contain 5-aminosalicylic acid (5-ASA), are 
often used to treat UC. The effectiveness of these aminosalicylate drugs is related to their 
mucosal concentration. Because free 5-ASA is rapidly absorbed in the small intestine, this 
drug must be encapsulated or conjugated to be effectively delivered to the colon. Methods 
for colonic delivery of 5-ASA include chemically attaching it to a carrier molecule or 
encapsulating it with pH or time-release polymers, but these methods exhibit various 
limitations (Caprilli et al., 2009).  
The use of polysaccharides as conjugate or encapsulation materials has been explored as a 
means of targeting the delivery of 5-ASA to the colon. The purpose of this chapter is to 
discuss approaches to using polysaccharides as colon-targeted drug delivery systems, and 
to discuss how using polysaccharides in these drug formulations may provide therapeutic 
benefits beyond drug delivery. 
1.1 Aminosalicylates in UC treatment  
Aminosalicylates were the first drugs that were shown to be effective against UC. The first 
of this class of drugs was sulphasalazine. At the time of this drug’s development, it was 
thought that both rheumatoid arthritis and UC were caused by streptococcal infection and 
that UC symptoms began in the connective tissue of the submucosa. Sulphasalazine was 
developed by combining sulphapyridine, which was effective against bacteria, with 5-ASA, 
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which was active on connective tissue. Sulphasalazine was shown to improve both 
rheumatoid arthritis and UC. At the recommended dose of 500mg 4 to 6 times per day, 
however, approximately 15 to 20% of patients experienced side effects such as headaches, 
nausea, vomiting, fever, cyanosis, allergic reactions, jaundice, leucopenia and agranulcytosis 
(Caprilli et al., 2009). Later research demonstrated that 5-ASA was the part of sulphasalazine 
responsible for the drug’s therapeutic effects against UC. Enemas of sulphasalazine, 5-ASA 
and sulphapyridine were given to patients with UC. Improvement was seen in only 5% of 
patients receiving sulphapyridine, as opposed to 30% of those receiving either sulphasalazine 
or 5-ASA (Azad Khan et al., 1977). This discovery paved the way for other 5-ASA-containing 
drugs developed for the treatment of UC. Today, aminosalicylates are still the standard 
therapy for the induction and maintenance of remission in UC patients (Hanauer, 2004).  
1.2 Mechanism of therapeutic action of aminosalicylate-containing drugs  
Aminosalicylate drugs are able to decrease the symptoms of UC, although the exact 
mechanism by which they act is unknown. Aminosalicylates have a demonstrated inhibitory 
effect on pro-inflammatory mediators released by the colonic and rectal mucosa. 5-ASA can 
interact with the peroxisome proliferator activated receptor ƴ, which acts to inhibit the 
mucosal production of inflammatory cytokines (Caprilli et al., 2009). 5-ASA also exhibits 
antioxidant properties, and can act as a free radical scavenger (Osterman & Lichtenstein, 
2009).    
Aminosalicylates act at the site of inflammation topically; the effectiveness of 5-ASA-
containing drugs is linked directly to their mucosal concentration. Therefore, it is necessary 
that aminosalicylates be delivered effectively to the colon. Delivery can be performed by 
administering the drug rectally or orally. When free 5-ASA is delivered orally, however, it is 
absorbed in the upper gastrointestinal tract, and does not reach the colon. Therefore, the 
drug must be protected in some way in order to ensure that it is delivered to the colon 
effectively (Caprilli et al., 2009).   
2. Current 5-aminosalicylic acid formulations: Varieties and limitations 
There are currently four main methods of orally delivering 5-ASA to the colon. These 
methods are through diazo compounds, pH-dependent formulations, time-controlled 
release, and a multi-matrix system (Table 1).   
In the first method, 5-ASA is attached to a carrier molecule by a diazo bond, which is then 
split by bacteria in the gastrointestinal tract. Commercial drugs of this type are known as 
Olsalazine, Balsalazide, and Sulphasalazine (Table 1). Sulphasalazine has been associated 
with numerous side effects, as explained, while Olsalazine and Balsalazide have not been 
shown to cause side effects (Sandborn, 2006a).  
The pH dependent release system involves an acid-resistant acrylic resin known as 
Eudragit-s. The acrylic protects the 5-ASA during its passage through the gastrointestinal 
tract, but is dissolved in the alkaline environment of the colon, releasing the 5-ASA (Dew et al., 
1982). Asacol is a commercial drug of this variety. A limitation of this delivery system is that a 
high degree of variation exists in the pH levels of the gastrointestinal tracts of different 
individuals, especially for those who are in a diseased state. Also, pH differences between the 
distal ileum, cecum and proximal colon are small. Therefore, it is difficult to determine exactly 
where in the gastrointestinal tract the 5-ASA will be released (Hanauer, 2004).  
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 Site of 
release 
Unit 
(g) 
Dose (g/d) 
 
Formulation Example Active Remission Limitations 
Conjugated 
5-ASA linked to 
sulfapyrazine by 
azo bond 
Sulfasalazine Colon 0.5 2-6 2-4 Diarrhea 
5-ASA dimer 
linked by azo-
bond 
Olsalazine Colon 0.5 Not 
effective 
1  
5-ASA linked to 
4-amino-benzoyl-
ǃ-alanine by azo 
bond 
Balsalazide Colon 0.75 4.6-7.5 4  
Encapsulated 
Eudragit-S 
coated tablets 
Asacol Ileum, 
colon 
0.4 1.6-4.8 0.8-1.6 No large 
change in 
pH from 
ileum to 
colon; pH 
differences 
among 
individuals 
Ethylcellulose-
coated micro-
granules (time-
release) 
Pentasa Small 
intestine, 
colon 
0.25-
1.0 
2-4 4 Variations 
in transit 
time 
Eudragit-L-
coated pellets 
with additional 
retarding 
polymer in the 
pellet core 
Mesalamine 
pellets 
Ileum, 
colon 
0.5 1.5-4.5 Not 
studied 
 
Eudragit-S-
coated tablets 
with lipophilic 
and hydrophilic 
matrices in the 
tablet core 
Lialda Ileum, 
colon 
1.2 2.4-4.8 Not 
studied 
 
Table 1. Aminosalicylate drugs: Examples, limitations, and doses (Sandborn, 2006b; Caprilli 
et al., 2009) 
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The time-controlled release system uses a microsphere of ethylcellulose to coat the 5-ASA. 
The microsphere swells and dissolves slowly as the drug moves through the gastrointestinal 
tract, releasing the 5-ASA mainly in the duodenum and proximal colon (Rasmussen et al., 
1982). Pentasa is the commercial name for this delivery system. As for the pH dependent 
release system, the major limitation of this drug type lies in patient variation. The time it 
takes for the drug to travel through the gastrointestinal tract can vary from person to 
person, leading to a non-specific point of drug release. Moreover, in patients with UC, 
transit time through the colon can be accelerated, leading to incomplete drug release (Jain et 
al., 2007).      
The newest delivery system developed for 5-ASA is the multimatrix, or MMX system. In 
this formulation, 5-ASA microparticles are trapped within a lipophilic matrix, which is 
then dispersed throughout a hydrophilic matrix. This tablet core is then coated with an 
acid-resistant polymer, which dissolves when the pH is above 7.0. When delivered via the 
MMX system, the 5-ASA is released beginning in the terminal ileum. This delivery system 
allows for slow release of 5-ASA along the length of the colon and rectum (Caprilli et al., 
2009). 
One limitation common to all of the drugs currently used to treat UC is the high dose 
needed to achieve therapeutic results (Table 1). Because the common dose of these 
aminosalicylate drugs is 225 to 500 mg per dose, patients may have to take over 10 pills per 
day in order to treat their conditions. This high pill burden often leads to low compliance 
rates among patients (Osterman & Lichtenstein, 2009).   
All formulations of 5-ASA are metabolized to N-acetyl-5-ASA by the same pathway. A 
meta-analysis looking at the fecal and systemic (urinary) excretion of N-acetyl-5-ASA using 
various formulations was carried out. A wide range of excretion amounts was found for 
each 5-ASA formulation, due to differences in study designs. However, a clear trend was 
spotted in regard to fecal vs. urinary excretion, based upon whether the patients in the 
studies had active or quiescent colitis. It was found that patients with active colitis had 
higher levels of 5-ASA in their feces, while those in remission had higher urinary levels of 
the drug. This is because UC causes a decrease in transit time through the gastrointestinal 
tract, providing less time for 5-ASA to be absorbed (Hanauer, 2004). Therefore, higher doses 
of 5-ASA are required to treat active UC, in comparison to amounts required to maintain 
remission (Table 1). 
3. Polysaccharides for colon-targeted drug delivery 
The use of various polysaccharides has been explored as a means of colon-targeted drug 
delivery. Polysaccharides provide several benefits as carrier molecules or encapsulation 
materials. They generally have a predictable degradation pattern, allowing for consistent 
release of the drug from the encapsulation matrix. Polysaccharide matrices also hydrate and 
swell as they travel through the gastrointestinal tract, creating a barrier against diffusion of 
the drug. When they arrive at the colon, colonic bacteria and enzymes are able to degrade 
the polysaccharide matrices to release the encapsulated drug (Wong et al., 2011).  
Polysaccharides also exist with a wide variety of functional groups, molecular weights, and 
chemical compositions. Some have a high stability to temperature and heat, while also 
having high biodegradability and low toxicity. Many polysaccharides are approved as 
pharmaceutical excipients (Jain et al., 2007).   
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Polysaccharides have been shown to be useful carrier systems for the delivery of 
aminosalicylates, in both encapsulation matrices and as conjugate carrier molecules. The 
rate of drug release can be tailored by controlling the polysaccharide carrier used and the 
method of preparation of the final 5-ASA-polysaccharide product (Wong et al., 2011). 
3.1 Encapsulation polysaccharides 
Several polysaccharides have been used successfully as encapsulation materials for 
aminosalicylate drugs, and are discussed below.  
3.1.1 Starch 
Enteric-coated starch capsules have been studied for the colon-targeted delivery of 
aminosalicylic acid. In one study, 5-ASA was placed into starch capsules produced by 
injection moulding, which were then covered with a Eudragit coating. The capsules were 
evaluated over time for capsule disintegration and drug release in gastric and intestinal 
media. The capsules were found to be stable in the gastric environment, but were 
disintegrated between one and two hours following immersion in the intestinal medium 
(Vilivalam et al., 2000). Another study by the same authors compared the release time of 5-
ASA from 5-ASA beads manufactured by extrusion-spheronization. 5-ASA beads in an 
uncoated starch capsule and 5-ASA beads in an enteric-coated starch capsule yielded similar 
time release results, but the 5-ASA in the coated starch capsule had the largest lag time in 5-
ASA release (Vilivalam et al., 2000).  
The amylose portion of starch has also been studied for use as a coating for the delivery of 5-
ASA to the colon, and similar results were seen as in the starch coating studies. A resin 
made of a combination of amylose and ethyl cellulose was used to coat 5-ASA pellets. The 
coated drug was stable in simulated gastric and small intestine solutions for 12 hours. The 5-
ASA was released within 4 hours when placed in a simulated colonic environment 
(Milojevic et al., 1996).  
3.1.2 Pectin 
Pectins are polysaccharides consisting of (1→4)-linked ǂ-D-galacturonic acid with 
intermittent (1→2)-linked ǂ-L-rhamnose units along the backbone with side chains of 
varying complexity containing galacturonic acid, galactose, rhamnose, arabinose, and other 
sugars. Most drug delivery studies use commercial pectin, which contains very few side 
chains (as these are removed during processing and purification). Backbone galacturonic 
acid units carry with them varying degrees of methylation. Low methyl esterified pectins 
can cross-link with divalent cations, which is important in encapsulation for drug delivery. 
Pectins are naturally resistant to gastric and small intestinal enzymes, but are degraded by 
colonic bacterial enzymes. They are soluble in water, which is a hurdle in the development 
of pectin-based drug delivery systems. This challenge can be overcome, however, through 
the choice of pectin type, the use of additives, or the use of accompanying hydrophobic 
polymers such as ethylcellulose (Jain et al., 2007).  
Pectins have been used successfully as matrix materials in several studies (Jain et al., 2007). 
For example, a pectin matrix cross-linked by calcium ions has been used to successfully 
deliver chemotherapy drugs to the colon (Wong et al., 2011). Another study found that a 
compression coat of high methoxy pectin was able to protect a core tablet during mouth to 
colon transit. The in vitro portion of this study showed that the pectin coat was able to 
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protect the tablet under gastric conditions. In vivo scintigraphic (radioactive tracing) results 
confirmed this, and also showed that the pectin-coated tablets dissolved once they reached 
the colon (Ashford et al., 1993). A mixture of pectin and chitosan has been shown to give 
protective results similar to a pectin coating, but with a lower coat weight (Fernandez-
Hervas, 1998).   
3.1.3 Inulin 
Inulin is a fructan consisting of 2 to 60 (2→1)-linked ǃ-D-fructose units, with glucose often 
as the initial moiety of the chain. It is a storage polysaccharide which is found in many 
plants, including onion, garlic, artichoke and chicory. Inulin is resistant to degradation in 
the upper gastrointestinal tract, but is preferentially fermented by Bifidobacteria in the colon 
(Jain et al., 2007).   
Inulin has been incorporated into Eudragit RS films, which are able to resist degradation in 
the upper gastrointestinal tract, but are metabolized by beneficial bacteria in the colon. 
Hydrogels of inulin have also been developed, in which vinyl groups are attached to 
inulin chains by free radical polymerization to induce intramolecular cross-linking (Van 
den Mooter et al., 2003). Methacrylated inulin has also been used as a hydrogel for 
targeted drug delivery. An in vitro stability study demonstrated that the higher the degree 
of substitution of the hydrogels, the more resistant they were to degradation by inulinase 
(Jain et al., 2007).  
3.1.4 Galactomannan-containing gums  
Galactomannan-containing gums have also been used as encapsulation materials for colon-
targeted drug delivery. One such gum is guar gum, which is obtained from the endosperm 
of Cyamposis tetragonolobus. It is comprised of a mannan backbone with galactose side 
chains. Guar gum can be used to coat colon-bound drugs by compression, retarding their 
release. The guar gum is then degraded in the large intestine by microbial enzymes, 
releasing the drug (Jain et al., 2007).  
Alternatively guar gum can used to encapsulate drugs through derivatization of the 
hydroxyl groups. In one study, guar gum was substituted with carboxymethyl groups, 
which were then cross-linked with barium ion. This was used as a microencapsulation 
matrix for a model compound: bovine serum albumin. Very little of the drug was released 
when the capsules were exposed to a pH of 1.2, simulating the stomach, but the drug was 
released in a pH of 7.4., simulating the large intestine. The researchers concluded that this 
formulation would be useful for gastrointestinal drug delivery (Thimma & Tammishetti, 
2001).  
Locust bean gum has also been used as an encapsulation material. Locust bean gum is 
derived from carob seeds, and is also a mannan with galactose side chains, though less 
branched then guar gum. In one study, locust bean gum was combined with chitosan in the 
ratios of 2:3, 3:2, and 4:1. The locust bean gum/chitosan mixture was applied to 5-ASA 
cores, which were created by tablet pressing and the stability of the formulation was tested 
in vitro and in vivo. The results of both studies showed that this coating was able to protect 
the drug from being released in the stomach and small intestine, but was degraded by 
colonic bacterial enzymes (Raghavan et al., 2002).  
The galactomannans in locust bean gum can be cross-linked, forming a water-insoluble film, 
which can then be degraded by bacteria in the colon (Hirsch et al., 1995). Locust bean gum 
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galactomannans were crosslinked by 1,4-butanedioldiglycidyl ether, yielding a low 
crosslinked product that can be used to form films. The crosslinked galactomannans were 
incubated anaerobically with the contents of a fresh pig cecum, representing the human 
colonic microflora, and degraded within 270 minutes. The material was then used to spray-
coat theophylline tablets, which were used as a model drug. When placed under conditions 
representing passage through the small intestine, drug release was observed, but the 
researchers concluded that the lag time prior to drug release could be increased by applying 
a thicker coating of the crosslinked galactomannans (Hirsch et al., 1995).  
3.1.5 Alginates  
Alginates, which are derived from seaweed, have not been used as an encapsulation 
material, but have been utilized as a core for aminosalicylate drugs. Alginates consist of 
(1→4) linked ǃ-D-mannuronic acid and ǂ-L-glucuronic acid residues. Alginates are able to 
form gels in the presence of divalent cations (Jain et al., 2007). In one study, calcium alginate 
beads were formed through the drop-wise addition of sodium alginate into a solution of 
calcium chloride. 5-ASA was spray coated on the calcium alginate beads and coated by pH-
dependent and time-released polymers. As the drug coated beads moved through the 
gastrointestinal tract, the calcium alginate beads swelled until they burst through the outer 
coatings due to an osmotic gradient, releasing the 5-ASA. This delivery system allows the 5-
ASA to be delivered to the ileum (Lin & Ayres, 1992).  
3.2 Conjugate polysaccharides  
In addition to their use as encapsulation materials, polysaccharides have been used as 
conjugate carrier molecules for the delivery of 5-ASA to the colon. The polysaccharides can 
be attached either to the carboxyl group or the amino group of the 5-ASA. Conjugates 
prepared by these methods have been shown to survive conditions in the stomach and small 
intestine and are able to reach the colon intact. In the colon, the 5-ASA is cleaved from the 
carrier molecule through the action of bacterial azo-reductases, esterases, and glycoside 
hydrolases.  
3.2.1 Dextran 
Dextrans are a class of polysaccharides consisting of linear chains of ǂ-D glucose molecules. 
Ninety five percent of the chains have glucose linked (1→6), while the side chains are linked 
(1→3). Dextrans are obtained from lactobacilli organisms. Bacteriodes in the gastrointestinal 
tract produce dextranase enzymes, which are capable of cleaving dextran chains (Jain et al., 
2007).  
Dextrans have been used as carrier molecules for 5-ASA in several studies. In one study, 
dextrans were oxidized using sodium periodate. The aldehyde groups of the dextrans were 
then attached to the ǂ-amino group of 5-ASA. Dextrans were oxidized by incubating them 
with different amounts of NaIO4. The amount of NaIO4 consumed was determined by back 
titration. The more NaIO4 consumed, the more oxidized the dextrans were considered to be. 
Degree of substitution was defined as the mg of 5-ASA per 100 mg of total product. Degrees 
of substitution between 15 and 50 were obtained, depending on the degree of oxidation of 
the dextran. It was found that dextrans with a high degree of oxidation gave the maximum 
degree of conjugation to 5-ASA, but were then resistant to hydrolysis by dextranase. Less 
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oxidized dextran bound a lower amount of 5-ASA, but were more able to be digested by 
dextranase, making them better candidates for carrier molecules (Ahmad et al., 2006).  In 
another study, dextran prodrugs of 5-ASA were created by linking the dextran to the 
carboxyl group of the 5-ASA via an ester linkage. The conjugates were incubated with small 
intestinal and caecal contents of rats. It was found that no 5-ASA was released during the 
incubation with the intestinal contents, but incubation with the caecal contents induced 
drug release (Jung et al., 1998).  
3.2.2 Cyclodextrins 
Cyclodextrins are cyclic oligosaccharides which are made up of six to eight ǂ-D-glucose 
units joined through (1→4) glycosidic bonds (Jain et al., 2007). There are three forms of 
cyclodextrins ǂ-Cyclodextrin is a six-membered ring, ǃ-cyclodextrin is a seven-membered 
ring, and ƴ-cyclodextrin is an eight-membered ring. Cyclodextrins are able to resist 
digestion in the stomach and small intestine, but are fermented in the colon. The interior of a 
cyclodextrin molecule is lipophilic, while the exterior is hydrophilic. This allows the 
cyclodextrins to form inclusion complexes with hydrophobic drugs (Zou et al., 2005).    
5-ASA was linked to ǂ, ǃ, and ƴ cyclodextrins through an ester linkage to the carboxyl group 
of the 5-ASA. The degree of substitution, or the percent of hydroxyl groups containing 5-
ASA, was measured. The impact of degree of substitution on the release of 5-ASA from 
cyclodextrin was also evaluated. It was found that cyclodextrins with degrees of 
substitution less than 30% provided the greatest release of 5-ASA in the caecal and colonic 
environment (Zou et al., 2005).  
4. Therapeutic agents as carrier molecules  
Using a therapeutic agent, rather than an inert compound, as the carrier molecule may 
improve the effectiveness of aminosalicylate drugs. Several polysaccharides have been 
shown to protect against UC inflammation, making them ideal candidates for carrier 
molecules (Ewaschuk, 2006). These polysaccharides can be incorporated into films, cross-
linked, or conjugated through ester linkages.  
There are several benefits of using polysaccharides as therapeutic carrier molecules. For one, 
drugs can be selectively released in the colon by bacterial esterases, rather than relying on 
gradual changes in pH or highly variable time release. Using polysaccharides can also allow 
for prolonged release of the drug in the distal colon, which is the site of most UC 
inflammation. The rate of release is dependent on the structure of the polysaccharide, as 
well as the activity of the bacterial esterases. Because polysaccharides have therapeutic 
benefits against UC, using them as carrier molecules might allow for a decrease in drug 
dosage requirements. On a lower dose of drugs, patients would likely experience fewer side 
effects, and patient compliance rates would increase. A polysaccharide carrier system would 
also increase the water solubility of the drugs. Increased solubility would allow for the 
administration of larger doses of the drug in beverage form, rather than in pills, which 
would also increase patient compliance.     
5. Therapeutic benefits for polysaccharides against UC  
Many of the polysaccharides described above are classified as dietary fibers. Dietary fiber 
encompasses a number of plant substances which are resistant to hydrolysis by digestive 
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enzymes in the small bowel. This includes non-starch polysaccharides, resistant starch, 
cellulose, hemicellulose, oligosaccharides, pectins, gums, lignin, and waxes (James et al., 
2003).  
When dietary fibers reach the large intestine, they are fermented by gut bacteria. In general, 
soluble dietary fiber is fermentable by colonic bacteria, producing short chain fatty acids, 
while insoluble fiber is poorly fermentable (Galvez et al., 2005). Different carbohydrate 
substrates produce different ratios of short chain fatty acids (SCFA). For example, resistant 
starch (RS) is butyrogenic, guar gum and psyllium are mainly propiogenic, while pectin is 
acetogenic (Rose & Hamaker, 2011).  
SCFA have many effects in the gastrointestinal tract. For example, SCFAs lower the pH of 
the lumen of the large bowel. This prevents the growth of some pathogenic bacteria. 
Butyrate, especially, is important for the maintenance of colonic health. Butyrate has 
been shown to prevent colonic inflammation by inhibiting NF-ĸB activation (Inan et al., 
2000). Butyrate may also help to prevent colon cancer, by playing a role in the repair of 
damaged DNA, and the induction of apoptosis in transformed epithelial cells (Lührs et 
al., 2002).  
In addition to producing SCFA, many polysaccharides are prebiotics. Prebiotics are food 
substances that are not digested in the small intestine and promote the growth of certain 
beneficial species of bacteria in the colon (Gibson et al., 2004). Prebiotics such as lactulose, 
fructo-oligosaccharides (FOS), inulin, psyllium, and germinated barley foodstuffs have been 
shown to stimulate the growth and metabolism of protective bacteria endogenous to the 
human gut (Ewaschuk & Dieleman, 2006). These protective bacteria can secrete metabolites 
that can help to reduce the amount of pro-inflammatory factors produced by the colonic 
mucosa. Bacteria that are thought to be beneficial to gut health include Lactobacilli, 
Bifidobacterium breve, Streptococcus thermophiles, B. bifidum, and Ruminococcus (Ewaschuk & 
Dieleman, 2006). Many of the carbohydrate carrier molecules discussed above are prebiotics, 
which stimulate the growth of these protective bacteria.  
5.1 Plantago ovata (psyllium) seeds   
Plantago ovata seeds, commonly known as psyllium, have been tested as remission 
maintenance treatments in UC. Psyllium seeds include a complex glucuronoarabinoxylan 
that is composed of a ǃ-(1→3 or →4)-D-Xylp backbone, with arabinoxylan, xylose, 
glucuronic acid and galactose side chains (Rose & Hamaker, 2011). One of the earliest 
studies looked at the effects of ingesting psyllium husks on quiescent UC patients. The 
researchers found that the psyllium husks were effective in reducing UC symptoms in these 
patients. Patients on the psyllium husk treatment reported decreased symptoms such as 
bloating, diarrhoea, and abdominal pain. The researchers hypothesized that the therapeutic 
benefit was primarily a result of the fiber’s normalizing effect on transit time through the 
bowel. Also, because psyllium husks are mainly composed of soluble fermentable fiber, 
their fermentation in the ascending colon would cause an increase in SCFA production, 
possibly leading to further health benefits (Hallert et al., 1991).  
 In another study, UC patients in remission were given 5-ASA, psyllium seed (which 
contains dietary fiber) or a combination of the two. No difference in disease states were 
observed between any of the treatment groups. This indicates that psyllium seed might be 
as effective a treatment for maintaining the remission of UC as the 5-ASA drug mesalamine. 
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This study also showed an increase in SCFA production in patients receiving psyllium 
(Fernandez-Banares et al., 1999). 
Plantago ovata seeds have also been shown to be therapeutic against an induced animal 
model of UC. Colitis was induced in rats via an enema containing 2,4,6,-trinitrobenzene 
sulfonic acid (TNBS).  There were 3 experimental groups; a non-colitic group, a colitic group 
which received a standard diet, and a colitic group which was fed a standard diet 
supplemented with psyllium seeds. Rats which received dietary fiber supplementation 
showed lower inflammation histologically, and had lower levels of myeloperoxidase, tumor 
necrosis factor ǂ, and nitric oxide synthase activity, some of the mediators involved in the 
inflammatory response (Rodriguez et al., 2002).  
5.1.1 Germinated barley foodstuff  
Germinated barley foodstuff (GBF) is made up of the aleurone layer and the scutellum 
fraction of brewer’s spent grain. GBF is comprised primarily of dietary fiber, in the form of 
low-lignified hemicellulose, and glutamine-rich protein. The dietary fiber portion of GBF is 
efficiently fermented by beneficial colonic bacteria such as Bifodobacterium and Lactobacillus, 
which increases the concentration of SCFA, especially butyrate, in the colonic lumen (Galvez 
et al., 2005).  
Several studies have examined the effects of GBF on patients with UC. In one study, patients 
with mild to moderately active UC were administered a conventional anti-inflammatory 
treatment, either with or without the addition of GBF. After 4 weeks on these regimens, 
patients who had GBF added to their treatment showed a significant decrease in clinical 
activity scores as compared to those who were on the conventional treatment only. There 
were no side effects observed with the GBF treatment, and faecal concentrations of the 
beneficial gut bacteria Bifidobacterium and Eubacterium limosum were increased (Kanauchi et 
al., 2002). An earlier study which also used GBF as a supplementation to traditional anti-
inflammatory treatment obtained similar results (Mitsuyama et al., 1998). Notably, this 
study found that inflammation significantly increased within 4 weeks of halting the GBF 
supplementation (Mitsuyama et al., 1998).  
Additionally, GBF can be used as a maintenance therapy to help maintain UC remission. 
When given to quiescent patients daily, in conjunction with traditional treatments, GBF 
was correlated with a reduction in UC symptoms. The rate of UC relapse was also lower 
in the group receiving GBF in addition to standard maintenance therapy (Hanai et al., 
2004).   
GBF has been shown to be effective in an animal model of UC. Kanauchi et al. (2003) 
demonstrated that GBF was therapeutic in treating mice with dextran sodium sulphate 
(DSS)-induced colitis. Mice were divided in to two groups and fed either a control diet of 
cellulose, or a diet containing GBF. After one week on each diet, experimental colitis was 
induced by adding 2% DSS to their drinking water, and the mice were sacrificed 6 days 
later.  The researchers found that mice that had been on the GBF diet showed significantly 
lower disease activity, weight loss, and inflammatory disease markers.  
5.1.2 Resistant starch  
RS is defined as starch and starch products which escape digestion in the human small 
intestine, acting as dietary fiber. In the large bowel RS is highly fermentable and contributes 
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greatly to colonic SCFA production. There are a number of types of RS: RS1 (physically 
inaccessibly starch), RS2a (uncooked starch), RS2b (high amylose starch), RS3 (retrograded 
starch), and RS4 (chemically modified starch). Some studies have demonstrated reduced 
postprandial glucose and insulin responses in patients who were fed RS. In animal models, 
RS has been shown to decrease serum lipid and cholesterol concentrations, although no such 
effect has been conclusively demonstrated in humans (Rose & Hamaker, 2010).  
RS has been shown to be therapeutic in an experimental animal model of colitis. Colitis was 
induced in rats via a TNBS enema. The animals were fed standard diets either with or 
without the addition of granular pea starch (a source of RS2). They were sacrificed between 
3 and 21 days after the induction of colitis, and the colons of the rats were examined. Rats 
which were fed diets including RS had an increased uptake of SCFA, and higher luminal 
concentrations of beneficial gut bacteria (Jacobasch et al., 1999).   
5.2 Lactulose  
Lactulose is a non-digestible disaccharide comprised of fructose and galactose produced 
by alkali isomerisation of lactose. It is not a common dietary carbohydrate, but is used in 
the pharmaceutical industry for the treatment of hepatic encephalopathy and 
constipation. It is a prebiotic carbohydrate, which is selectively digested by bacteria in the 
cecum and colon.  
Lactulose was proposed as a possible treatment for UC based upon its demonstrated ability 
to clear infectious bacteria and bacterial endotoxins from the gastrointestinal tract (Liao et 
al., 1994). Lactulose was then tested for efficacy in treating a DSS-induced mouse model of 
colitis (Rumi et al., 2004). In this study, colitis was induced in the mice through the addition 
of DSS to their drinking water over a period of 7 days. The mice were then treated orally 
with lactulose twice daily for 6 days. Compared to control animals, mice treated with 
lactulose exhibited decreased UC symptoms such as colonic ulceration and myeloperoxidase 
activity. The prebiotic properties of lactulose are believed to be responsible for its 
therapeutic potential in treating UC (Rumi et al,. 2004).  
5.3 Fructooligosaccharides and inulin  
FOS are composed of (1→2)-linked ǃ-D-fructose units, with a terminal glucose unit (Rose & 
Hamaker 2011).   FOS are resistant to digestion in the small intestine, and are fermented in 
the colon by gut bacteria (Le Blay et al., 1999). In one study, FOS were administered to rats 
with TNBS-induced colitis through intragastric infusions at a level of 1g/day for two weeks. 
The FOS were found to decrease the rats’ gross inflammation score, myeloperoxidase 
activity and pH, and to increase the lactate, butyrate, and lactic acid-producing bacteria 
concentrations. The therapeutic effects of FOS are thought to be primarily due to their ability 
to increase lactic acid-producing bacteria counts in the intestine (Cherbut et al,. 2003). In 
contrast, Moreau et al. (2007) showed that FOS were ineffective in improving DSS-induced 
colitis in rats, as compared with RS.  The differences between the effects of these two 
carbohydrates could be due to differences in SCFA and pH profiles produced through 
bacterial fermentation in the colon.    
Inulin is the same basic structure as FOS, except includes longer chain fractions (up to 60 
units). Inulin is a prebiotic, and has been shown to be effective in treating UC. Inulin has 
been demonstrated to improve the symptoms of DSS-induced UC in a rat model. Rats with 
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DSS-induced colitis received inulin either orally or through an enema. Inulin given through 
an oral route was shown to decrease inflammation in the rats, while the inulin given via 
enema had no effect (Videla et al., 2001).  
In a human clinical study, oligofructose-enriched inulin, which is a 50:50 mixture of FOS 
and long-chain inulin, was shown to alleviate inflammation associated with UC. The 
patients had been in remission with either 5-ASA maintenance or without any drug, and 
had experienced a relapse of their UC. The patients were treated with a combination of 5-
ASA and oligofructose-enriched inulin or a placebo for a period of two weeks. Fecal 
calprotectin was measured as a marker of inflammation. Patients who received the 
oligofructose-enriched inulin showed lower fecal calprotectin levels than the control group, 
indicating that oligofructose-enriched inulin is able to reduce inflammation from UC 
(Casellas et al., 2007).  
6. Conclusions  
This chapter has discussed the use of polysaccharides for colon-targeted drug delivery. 
Polysaccharides offer several advantages over traditional colon-targeted drug delivery 
systems. For instance, polysaccharides are natural polymers with no toxicity. Furthermore, 
the variation in structure and mode of conjugation/encapsulation could lead to improved 
site-specific drug release, reducing the need for excessive amounts of the drug. Finally, 
polysaccharides may lead to reduction in disease severity beyond that provided by the drug 
due to fermentation of the polysaccharide by bacteria. In this way, the polysaccharides not 
only act as carrier molecules, but as therapeutic agents as well.   
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